Pfizer said Wednesday that new test results show its coronavirus vaccine is 95% effective, is safe and also protects older people most at risk of dying — last data needed to seek emergency use of limited shot supplies even as the catastrophic outbreak worsens across the globe.

The announcement from Pfizer and its German partner BioNTech, just a week after they revealed the first promising preliminary results, comes as the team is preparing within days to formally ask U.S. regulators to allow emergency use of the vaccine.

They also have begun “rolling submissions” for the vaccine with regulators in Europe, the U.K. and Canada and soon will add this new data.

Pfizer and BioNTech had initially estimated the vaccine was more than 90% effective after 94 infections had been counted in a study that included 44,000 people. With the new announcement, the company now has accumulated 170 infections in the study — and said only eight of them occurred in volunteers who got the actual vaccine rather than a dummy shot. One of those eight developed severe disease, the company said.

“This is an extraordinarily strong protection,” Dr. Ugur Sahin, BioNTech’s CEO and co-founder, told The Associated Press.

The companies have not yet released detailed data on its study, and results have not been analyzed by independent experts. Also still to be determined are important questions such as how long protection lasts and whether people might need boosters.

But all eyes are on the progress of potential vaccines as the grim infection rate jumps in the U.S. and abroad as winter weather forces people indoors, in the close quarters that fuels viral spread.

Pfizer and BioNTech said the vaccine was more than 94% effective in adults over age 65, though it is not clear exactly how that was determined with only eight infections in the vaccinated group to analyze and no breakdown provided of those people’s ages.

Sahin said there were enough older adults enrolled in the study and among the placebo recipients who became infected that he is confident “this vaccine appears to work in the higher-risk population.”

Earlier this week Moderna, Inc. announced that its experimental vaccine appears to be 94.5% effective after an interim analysis of its late-stage study.

Similar results from two vaccines both made with a brand-new technology — using a snippet of the genetic code of the coronavirus to train the body to recognize if the real virus comes along — likely will add to experts’ reassurance about the novel approach.

While initial supplies will be scarce and rationed, as the supply grows Sahin said the companies have a responsibility to help ensure access for lower income countries as well.

Pfizer and BioNTech also say now have the required data on the vaccine’s safety needed to seek emergency authorization from the Food and Drug Administration.

The companies didn’t disclose safety details but said no serious vaccine side effects have been reported, with the most common problem being fatigue after the second vaccine dose, affecting about 4% of participants.

The study has enrolled nearly 44,000 people in the U.S. and five other countries. The trial will continue to collect safety and effectiveness data on volunteers for two more years.

Pfizer and BioNTech said they expect to produce up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses in 2021.

U.S. officials have said they hope to have about 20 million vaccine doses each from Moderna and Pfizer available for distribution in late December. The first shots are expected to be offered to vulnerable groups like medical and nursing home workers, and people with serious health conditions.

Photo via University of Maryland School of Medicine and AP.

Related Stories
‹
Pfizer Says COVID-19 Vaccine Is Looking 90% Effective
Pfizer said Monday that an early peek at the data on its coronavirus vaccine suggests the shots may be a robust 90% effective at preventing COVID-19, putting the company on track to apply later this month for emergency-use approval from the Food and Drug Administration. The announcement, less than a week after a presidential election […]
Pfizer Seeking Emergency Use of Its COVID-19 Vaccine in U.S.
Pfizer said Friday it is asking U.S. regulators to allow emergency use of its COVID-19 vaccine, starting the clock on a process that could bring limited first shots as early as next month and eventually an end to the pandemic — but not until after a long, hard winter. The action comes days after Pfizer […]
Pfizer, US Ink $5.29B Deal for Possible COVID-19 Treatment
Written by TOM MURPHY The U.S. government will pay drugmaker Pfizer $5.29 billion for 10 million treatment courses of its potential COVID-19 treatment if regulators authorize it, the nation’s largest purchase agreement yet for a coronavirus therapy. Pfizer asked the Food and Drug Administration on Tuesday to authorize emergency use of the experimental pill, which […]
U.S. Prison Guards Refusing Vaccine Despite COVID-19 Outbreaks
Written by NICOLE LEWIS of The Marshall Project and MICHAEL R. SISAK of The Associated Press. A Florida correctional officer polled his colleagues earlier this year in a private Facebook group: “Will you take the COVID-19 vaccine if offered?” The answer from more than half: “Hell no.” Only 40 of the 475 respondents said yes. In […]
‘Overwhelm the Problem’: Inside Biden’s War on COVID-19
The meetings begin each day not long after dawn. Dozens of aides report in, coffee in hand, joining by Zoom from agency headquarters, their homes or even adjacent offices. The sessions start with the latest sobering statistics meant to focus the work and offer a reminder of what’s at stake: new coronavirus cases, people in […]
J&J 1-Dose Shot Prevents COVID-19, but Less Than Some Others
Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate […]
Lucky Few Hit COVID-19 Vaccine Jackpot for Rare Extra Doses
Fortune struck one man in the bakery aisle at the supermarket. Two others were working the night shift at a Subway sandwich shop. Yet another was plucked from a list of 15,000 hopefuls. With millions of Americans waiting for their chance to get the coronavirus vaccine, a lucky few are getting bumped to the front […]
U.S. Close on Deal With Pfizer for Millions More Vaccine Doses
The U.S. government is close to a deal to acquire tens of millions of additional doses of Pfizer’s vaccine in exchange for helping the pharmaceutical giant gain better access to manufacturing supplies. A person with knowledge of the negotiations told The Associated Press on Tuesday that the deal is under discussion and could be finalized […]
Pfizer COVID-19 Vaccine Faces Last Hurdle Before U.S. Decision
Pfizer’s COVID-19 vaccine faces one final hurdle as it races to become the first shot greenlighted in the U.S.: a panel of experts who will scrutinize the company’s data for any red flags. Thursday’s meeting of the Food and Drug Administration’s vaccine advisory panel is likely the last step before a U.S. decision to begin […]
‘Route Out’ of Pandemic: U.K. Gives 1st COVID-19 Vaccine Doses
A retired British shop clerk received the first shot in the country’s COVID-19 vaccination program Tuesday, the start of an unprecedented global immunization effort intended to offer a route out of a pandemic that has killed 1.5 million. Margaret Keenan, who turns 91 next week, got the shot at 6:31 a.m. on what public health […]
›